Thalidomide plus oral melphalan for advanced multiple myeloma: A phase II study

Massimo Offidani, Monica Marconi, Laura Corvatta, Attilio Olivieri, Massimo Catarini, Pietro Leoni

Research output: Contribution to journalArticlepeer-review

Abstract

Thalidomide exerts synergistic or additive effects when combined with other drugs. This study reports the toxicity and efficacy of the combination of thalidomide plus oral melphalan in 27 patients with advanced multiple myeloma. We found that this combination induces a high response rate and a long progression-free survival without significantly increasing thalidomide-related toxicity.

Original languageEnglish
Pages (from-to)1432-1433
Number of pages2
JournalHaematologica
Volume88
Issue number12
Publication statusPublished - Dec 2003

Keywords

  • Melphalan
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Thalidomide plus oral melphalan for advanced multiple myeloma: A phase II study'. Together they form a unique fingerprint.

Cite this